Cavazzoni Patrizia, Tanaka Yoko, Roychowdhury Suraja M, Breier Alan, Allison David B
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 1 Corporate Plaza, DC 6314, Indianapolis, IN 46285, USA.
Eur Neuropsychopharmacol. 2003 Mar;13(2):81-5. doi: 10.1016/s0924-977x(02)00127-x.
Weight gain is associated with treatment with olanzapine and other psychotropic agents. Nizatidine, a histamine H-2 receptor antagonist, has been proposed to have weight-reducing effects. This double-blind trial evaluated the efficacy of nizatidine in limiting weight gain in patients with schizophrenia and related disorders who were treated with olanzapine for up to 16 weeks. After an initial screening period, 175 patients were randomized to receive olanzapine (5-20 mg) with either placebo or nizatidine (150 mg b.i.d. or 300 mg b.i.d.). Significantly less weight gain was observed on average at weeks 3 and 4 with olanzapine+nizatidine 300 mg b.i.d. (P<0.05) compared to olanzapine+placebo, but the difference was not statistically significant at 16 weeks. Nizatidine was well-tolerated and did not adversely affect clinical outcomes. Nizatidine 300 mg b.i.d. may have an early transient effect in limiting the weight gain, but this potential early effect appeared to be diminished or eliminated by 16 weeks.
体重增加与使用奥氮平和其他精神药物治疗有关。组胺H2受体拮抗剂尼扎替丁被认为具有减轻体重的作用。这项双盲试验评估了尼扎替丁对接受奥氮平治疗长达16周的精神分裂症及相关疾病患者限制体重增加的疗效。在初始筛查期后，175名患者被随机分配接受奥氮平（5 - 20毫克）加安慰剂或尼扎替丁（每日两次，每次150毫克或每日两次，每次300毫克）。与奥氮平加安慰剂相比，在第3周和第4周时，平均观察到奥氮平加每日两次300毫克尼扎替丁组体重增加明显较少（P<0.05），但在16周时差异无统计学意义。尼扎替丁耐受性良好，且对临床结果无不良影响。每日两次300毫克尼扎替丁在限制体重增加方面可能有早期短暂作用，但这种潜在的早期作用在16周时似乎减弱或消失。
